Even with three COVID-19 vaccines authorized in the U.S. and others possibly available soon, two UW-Madison spinoff companies continue to pursue coronavirus vaccine candidates they say could find a niche.
Even with three COVID-19 vaccines authorized in the U.S. and others possibly available soon, two UW-Madison spinoff companies continue to pursue coronavirus vaccine candidates they say could find a niche.